|
CA2974884A1
|
|
Multi-epitopic construct
|
|
GB201510195D0
|
|
Multi-epitopic construct
|
|
GB201501354D0
|
|
Multi-epitopic construct
|
|
GB201206761D0
|
|
Anti-atherogenic peptides
|
|
CA2758213A1
|
|
Anti-atheroma vaccine
|
|
GB0822828D0
|
|
Target
|
|
GB0807579D0
|
|
Vaccine composition and method
|
|
GB0806461D0
|
|
Anti-atheroma vaccine
|
|
GB0709373D0
|
|
BCG-based anti-atheroma vaccine
|
|
GB0706540D0
|
|
Anti-atheroma vaccine
|
|
GB0606256D0
|
|
Anti-atheroma vaccine
|
|
GB0503000D0
|
|
Anti-atheroma vaccine
|
|
GB0211515D0
|
|
Blood treatment
|
|
GB9705787D0
|
|
Modified dendroaspins
|
|
GB9613719D0
|
|
Serine protease inhibitors
|
|
GB9613718D0
|
|
Thrombin inhibitors
|
|
GB9502985D0
|
|
Enzyme inhibitors
|
|
US5648338A
|
|
Inhibitors and substrates of thrombin
|
|
US5574014A
|
|
Inhibitors of trypsin-like enzymes
|
|
GB9321861D0
|
|
Platelet derived growth factor analogues
|
